Intuitive Surgical, Inc. ISRG is well-poised for growth in the coming quarters, courtesy of its strength in robotics. The optimism, led by solid results in the last few quarters and its progress on the Artificial Intelligence (AI) front, is expected to contribute further. However, procedure adoption risks and stiff competition persist. Shares of this Zacks Rank #2 (Buy) company have risen 31.8% year to date compared with the industry’s 2.9% growth. The S&P 500 Index has gained 17.7% during the same time frame. Intuitive Surgical, the pioneer of robotic-assisted surgery and a renowned provider of minimally invasive care, has a market capitalization of $156.88 billion. It projects 16.1% growth over the next five years. The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 6.78%. Zacks Investment Research Image Source: Zacks Investment Research Let’s delve deeper. Strength in Robotics: We are upbeat about Intuitive Surgical’s robot-based da Vinci surgical system that enables minimally invasive surgery and reduces the trauma associated with open surgery. The da Vinci System is powered by robotic technology that has provided the company with solid exposure to medical mechatronics, robotics and AI for the healthcare space. The company has gained FDA clearance for its da Vinci 5 fifth-generation multiport robotic system, earlier this month. The system is believed to be the smoothest and most accurate device in ISRG’s portfolio. On its first-quarter 2024 earnings call, the company stated that its installed base of the da Vinci system grew approximately 14% year over year. The utilization of clinical systems in the field, measured by procedures per system, was up 2% from the prior-year quarter’s level. Progress on the AI Front: We are also positive about the growing adoption of minimally invasive robot-assisted surgeries, self-automated home-based care, the use of information technology for quick and improved patient care, and the shift of the payment system to a value-based model. These developments indicate the high prevalence of AI in the MedTech space. Per management, the rise of medical mechatronics, powerful computing, improved sensing, microfabrication and molecular imaging has enabled new solutions to old problems. AI has been enhancing Intuitive Surgical’s product portfolio with clinical applications, diagnostic support, operational efficiency, electronic health record systems, practice workflows and supply-chain management. Strong Q1 Results: ISRG’s solid first-quarter results also buoy optimism. Revenues were primarily driven by continued growth in the company’s da Vinci procedure volume. Intuitive Surgical has been raising the price of procedures to fight inflationary pressure, which also aided sales growth.Meanwhile, the absence of any significant disruptions from COVID during the first quarter aided results and may continue to boost procedure growth going forward.The gross and operating margins also improved. The declining trend in operating expenses is likely to continue for the rest of 2024 as well. Downside Supply Constraints Hurting Performance: Intuitive Surgical has been facing supply constraints for several instruments, leading to a loss of sales (as the company fails to meet demand). The ongoing geopolitical tensions with no resolution in the picture indicate that supply-chain issues are likely to persist, thereby continuing to hurt sales. The company expects da Vinci 5 system placements to be choppy in 2024 due to constrained supply, thereby hurting growth prospects for the device. Customers may delay orders and wait for adequate supply before buying the fifth-generation da Vinci 5. Although the extension of catheter life for the Ion modulation system should boost supply, catheter supply is likely to remain challenging. Estimate Trend In the past 60 days, the Zacks Consensus Estimate for 2024 earnings has remained stable at $6.26 per share. The consensus mark for the company’s revenues is pegged at $8.01 billion, indicating a 12.5% improvement from the year-ago quarter’s reported number. Other Stocks to Consider Some other top-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, DexCom DXCM and Universal Health Services UHS. DaVita, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. DaVita’s shares have risen 33% year to date compared with the industry’s 3.9% growth. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22.9%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 34.1%. DexCom’s shares have lost 10.7% against the industry’s 2.9% growth year to date. Universal Health Services has an estimated long-term growth rate of 15.2% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Universal Health Services’ shares have risen 18.2% year to date compared with the industry’s 18.1% growth. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS):Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report DexCom, Inc. (DXCM):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...